Responses
Poster Presentation
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
Compose a Response to This Article
Other responses
No responses have been published for this article.